Table 4.
Week −1 | Week 2 | Week 5 | Week 11 | SEM1 | |||||
---|---|---|---|---|---|---|---|---|---|
Pre-run | Post-run | Pre-run | Post-run | Pre-run | Post-run | Pre-run | Post-run | ||
Treatment | |||||||||
Trp, μM | 67.8b | 73.8ab | 74.1ab | 87.2ab | 90.3ab | 107.0a | 83.0ab | 97.9ab | 9.0 |
LNAA2, μM | 524.9b | 552.4b | 538.4b | 566.7b | 652.5ab | 744.5a | 673.2ab | 771.0a | 38.5 |
Trp:LNAA3 | 0.13 | 0.13 | 0.14 | 0.14 | 0.14 | 0.15 | 0.12 | 0.13 | 0.018 |
5-HT, ng/mL | 109.99 | 113.55 | 107.70 | 116.79 | 121.14* | 122.09* | 124.11* | 127.12* | 7.51 |
Control | |||||||||
Trp, μM | 65.3 | 79.8 | 67.7 | 74.3 | 68.3 | 85.8 | 72.1 | 85.8 | 9.8 |
LNAA2, μM | 521.3b | 554.3b | 529.0b | 570.5ab | 605.9ab | 678.8ab | 689.6ab | 816.3a | 42.1 |
Trp:LNAA3 | 0.13 | 0.14 | 0.13 | 0.13 | 0.11 | 0.13 | 0.10 | 0.11 | 0.019 |
5-HT, ng/mL | 105.54 | 110.34 | 106.66 | 108.44 | 103.65 | 104.26 | 102.10 | 105.41 | 8.11 |
1Treatment, n = 8 (weeks −1, 2, and 5), n = 7 for treatment (week 11) and control (weeks −1, 2, and 5), n = 6 for control (week 11).
2LNAA: Val, Phe, Ile, Leu, Tyr.
3Ratio of Trp to LNAA.
a,bValues in a row with different superscript are different (P ≤ 0.05).
*Significantly different (P ≤ 0.05) when compared with the equivalent control at the same sampling time point within week.